AJMC® in the Press, December 5, 2025

An article published in Insurance Newsnet referenced a study published in the August 2025 issue of The American Journal of Managed Care^® (AJMC^®). The study, “Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns,” concluded that the prescribing rate of glucagon-like peptide-1 receptor agonists increased between 2018 and 2023, with semaglutide rising to 60% share in nondiabetic obese/overweight patients.

A study entitled, “Social Determinants of Health and High-Cost Utilization Among Commercially Insured Population,” published in the July 2023 issue of AJMC, was referenced in an article published in Healthcare Brew. The study found that living in disadvantaged neighborhoods was associated with being a high-cost utilizer of health care, specifically in adults 65 years and older.

Articles from LiveScience and UConn Today referenced an article published on AJMC.com, the website of AJMC. The article, “NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants,” covered the results of a research letter, which found that 694 National Institutes of Health (NIH) grants were terminated between February 28 and April 8 of 2025.

An article from AJMC entitled, “Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP,” was referenced in an article from ADA News. The article from AJMC reported on the approval of tezepelumab (Tezspire; AstraZeneca/Amgen) by the FDA, which can help patients 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps.

An article from Lawyer Monthly referenced an article published on AJMC.com. The article, “How Insurance Claim Denials Harm Patients’ Health, Finances,” focused on how delays in receiving coverage for conditions such as diabetes can increase costs, add stress, and worsen symptoms in patients who need it.